BUFFALO GROVE, Ill., March 5, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present at the ROTH Capital Partners 27th Annual Growth Stock Conference, being held March 8-11, 2015, in Dana Point, CA. Mr. Simes will provide a corporate overview on Tuesday, March 10, at 4:30pm PT. The presentation will be webcast and available for 90 days at http://wsw.com/webcast/roth29/resx/
About RestorGenex Corporation
RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com.
About the ROTH Conference
One of the largest of its kind, ROTH's flagship three-day investment conference brings together executives from more than 530 public and private companies and approximately 1,000 investors. Company presentations, Q&A sessions, panels and management one-on-one meetings offer investor clients opportunities for extensive interaction with executive management to gain in-depth insights into each business and sector.
CONTACT: The Trout Group LLC Marcy Nanus, 646-378-2927 firstname.lastname@example.orgSource:RestorGenex